Therapeutic Solutions International, Inc. manufactures surgical and medical devices. It also produces nutraceuticals. The firm develops a range of immune-modulatory agents to target cancers, enhance maternal and fetal health, and fight periodontal disease, as well as for daily health. The company was founded on August 6, 2007 and is headquartered in Oceanside, CA.
Company profile
Ticker
TSOI
Exchange
Website
CEO
Timothy G. Dixon
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Friendly Auto Dealers, Inc.
SEC CIK
Corporate docs
IRS number
331176182
TSOI stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
17 Apr 24
NT 10-K
Notice of late annual filing
1 Apr 24
8-K
Amendments to Articles of Incorporation or Bylaws
21 Feb 24
8-K
Amendments to Articles of Incorporation or Bylaws
20 Feb 24
EFFECT
Notice of effectiveness
8 Feb 24
S-1/A
IPO registration (amended)
6 Feb 24
CORRESP
Correspondence with SEC
6 Feb 24
UPLOAD
Letter from SEC
30 Jan 24
8-K
Other Events
22 Jan 24
S-1
IPO registration
17 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 90.14 k | 90.14 k | 90.14 k | 90.14 k | 90.14 k | 90.14 k |
Cash burn (monthly) | 10.98 k | 1.26 k | 200.95 k | 223.57 k | 103.69 k | 101.19 k |
Cash used (since last report) | 72.85 k | 8.35 k | 1.33 mm | 1.48 mm | 687.93 k | 671.34 k |
Cash remaining | 17.28 k | 81.78 k | -1.24 mm | -1.39 mm | -597.79 k | -581.20 k |
Runway (months of cash) | 1.6 | 64.9 | -6.2 | -6.2 | -5.8 | -5.7 |
Institutional ownership, Q4 2021
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
26 Feb 24 | Ichim Thomas | Common Stock | Grant | Acquire A | No | No | 0.0009 | 10,000,000 | 9.00 k | 152,000,000 |
26 Feb 24 | Dixon Timothy G | Common Stock | Grant | Acquire A | No | No | 0.0009 | 10,000,000 | 9.00 k | 368,993,103 |
16 Oct 23 | Dixon Timothy G | Common Stock | Grant | Acquire A | No | No | 0.0015 | 70,000,000 | 105.00 k | 358,993,103 |
16 Oct 23 | Ichim Thomas | Common Stock | Grant | Acquire A | No | No | 0.0015 | 20,000,000 | 30.00 k | 142,000,000 |
5 Jan 23 | Dixon Timothy G | Common Stock | Grant | Acquire A | No | No | 0.0049 | 4,081,632 | 20.00 k | 288,993,103 |
Press releases
Therapeutic Solutions International Granted Patent on Commercially Available QuadraMune® Nutraceutical for Increasing Natural Killer Cell Immunity in COVID-19 Patients
4 Mar 24
Therapeutic Solutions International Files Patent on "Facilitating Effects" of JadiCells on Gene Therapy Mediated Cell Differentiation
26 Feb 24
Therapeutic Solutions International Files Lawsuit in San Diego Superior Court to Obtain Identities of Certain Individuals or Entities
22 Jan 24